Literature DB >> 10092133

Frequent allelic loss at the TOC locus on 17q25.1 in primary breast cancers.

K Fukino1, A Iido, A Teramoto, G Sakamoto, F Kasumi, Y Nakamura, M Emi.   

Abstract

Sporadic breast cancers often show allelic losses on the long arm of chromosome 17. Since the BRCA1 gene lies at 17q21.1 and the TOC locus, associated with esophageal cancer, lies at 17q25.1, either gene could be the target of those losses. We examined both loci in 178 primary breast cancers, using microsatellite markers covering the relevant regions of 17q, and observed allelic losses in 97 tumors (55%). Losses were most frequent at markers around the TOC locus (48% at D7S1839 and 43% at D17S1603), where we identified a distinct commonly deleted region within a I -cM interval. Another larger, separate commonly deleted region including the BRCA1 gene was also identified, which exhibited 45% of allelic loss (at D17S934). Allelic loss on 17q was more frequent in tumors of the solid-tubular histologic type (P = 0.0129) and in estrogen-negative and progesterone-negative tumors (P = 0.0281 and 0.0196, respectively). The results indicated that BRCA1 and TOC are independent targets of allelic loss on 17q in primary breast cancers, and that inactivation of the TOC locus in particular may play an important role in the genesis of sporadic breast tumors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10092133     DOI: 10.1002/(sici)1098-2264(199904)24:4<345::aid-gcc8>3.0.co;2-q

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  5 in total

1.  Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning.

Authors:  Stephanie N Dorman; Katherina Baranova; Joan H M Knoll; Brad L Urquhart; Gabriella Mariani; Maria Luisa Carcangiu; Peter K Rogan
Journal:  Mol Oncol       Date:  2015-08-22       Impact factor: 6.603

2.  Platelet-derived growth factor receptor association with Na(+)/H(+) exchanger regulatory factor potentiates receptor activity.

Authors:  S Maudsley; A M Zamah; N Rahman; J T Blitzer; L M Luttrell; R J Lefkowitz; R A Hall
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

3.  Down-regulation in multiple human cancers of a novel gene, DMHC, from 17q25.1 that encodes an integral membrane protein.

Authors:  I Mikami; H Harada; H Nagai; M Tsuneizumi; Y Nobe; K Koizumi; S Sugano; S Tanaka; M Emi
Journal:  Jpn J Cancer Res       Date:  2001-04

4.  Association of allelic losses at 3p25.1, 13q12, or 17p13.3 with poor prognosis in breast cancers with lymph node metastasis.

Authors:  S Haga; M Emi; A Hirano; Y Utada; T Kajiwara; F Akiyama; G Sakamoto; K Takahashi; T Tada; F Kasumi; Y Miki; Y Nakamura
Journal:  Jpn J Cancer Res       Date:  2001-11

5.  Allelotype of 28 human breast cancer cell lines and xenografts.

Authors:  I C Harkes; F Elstrodt; W N M Dinjens; M Molier; J G M Klijn; E M J J Berns; M Schutte
Journal:  Br J Cancer       Date:  2003-12-15       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.